Solan Headlines

Psoriasis Drugs Market Share, Future Opportunity, Geographical Regions, Key Manufacturers and Industry Forecasts 2021-2030

 Breaking News
  • No posts were found

Psoriasis Drugs Market Share, Future Opportunity, Geographical Regions, Key Manufacturers and Industry Forecasts 2021-2030

January 13
15:00 2022
Psoriasis Drugs Market Share, Future Opportunity, Geographical Regions, Key Manufacturers and Industry Forecasts 2021-2030
Geographically, the Asia-Pacific is expected to be the fastest-growing region in the psoriasis drugs market during the forecast period.

The global psoriasis drugs market revenue stood at $14,504.0 million in 2020, and it is expected to surge to $53,210.6 million by 2030. According to the estimates of the market research company, P&S Intelligence, the market will progress at a CAGR of 14.0% from 2021 to 2030 (forecast period). The market is being propelled by the mushrooming population of geriatric people, surging incidence of psoriasis, growing per capita income, soaring healthcare expenditure, and increasing number of research programs across the world.

According to the World Population Ageing 2020 report published by the United Nations Department of Economic and Social Affairs (UNDESA), the population of people aged 65 years or above will rise from 727 million in 2020 to more than 1.5 billion by 2050. As the functionality of the skin reduces with increasing age and the skin becomes vulnerable to various issues, such as the loss of subcutaneous fat, slow healing of wounds, greater sensitivity to ultraviolet (UV) radiation, and higher susceptibility to various skin diseases and infections, such as psoriasis, the booming population of geriatric people is positively impacting the worldwide demand for psoriasis drugs.

Get the sample pages of this report at: https://www.psmarketresearch.com/market-analysis/psoriasis-drugs-market-outlook/report-sample

Besides, the rising incidence of psoriasis is also propelling the advancement of the psoriasis drugs market. As per the National Psoriasis Foundation, 125 million people all over the world were living with psoriasis in 2020, which was considerably higher than the number of people diagnosed with the disease in 2016, which stood at around 100 million. Depending on type, the psoriasis drugs market is divided into small-molecule systematic rugs, topical therapies, and biologic drugs. Out of these, the biologic drugs category contributed the highest revenue to the market in the past, primarily because of the increasing patient pool around the world.

Additionally, the surging private and public funding being provided to various research programs associated with the disease is fueling the development of effective and highly targeted biologic drugs, thereby pushing up the demand for psoriasis drugs. Globally, the Asia-Pacific (APAC) region is predicted to be the fastest-growing region in the psoriasis drugs market in the coming years. This is credited to factors, such as the rising prevalence of skin diseases, growing disposable income of people, which is resulting in increased expenditure on skincare products, launch of advanced medications, rapidly improving healthcare infrastructure, and existence of various market players in the region.

Browse detailed report on Psoriasis Drugs Market Size, Share, Growth, Demand and Forecast Report, 2030

The players operating in the industry are focusing on product approvals and launches in order to strengthen their position. For example, Janssen, which is the pharmaceutical division of Johnson & Johnson, announced in July 2020 that it has received approval from the Food and Drug Administration (FDA) for the use of TREMFYA (guselkumab) in adult patients suffering from active psoriatic arthritis (PsA). TREMFYA is administered as a 100-mg subcutaneous injection every eight weeks after two starter doses at weeks 0 and 4.

Hence, the demand for psoriasis drugs will shoot up across the world in the coming years, primarily because of the growing incidence of psoriasis and ballooning population of geriatric people across the world.

Psoriasis Drugs Market Size Breakdown by Segment

By Type

  • Biologic Drugs
  • Small-Molecule Systemic Drugs
  • Topical Therapies

By Mechanism of Action

  • Tumor Necrosis Factor (TNF)-Alpha Inhibitors
  • Phosphodiesterase Type 4 (PDE4) Inhibitors
  • Interleukin Inhibitors
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical

By Region

  • North America Psoriasis Drugs Market
    • By type
    • By MoA
    • By RoA
    • By country – U.S. and Canada
      • U.S. psoriasis drugs market
        • By type
        • By MoA
        • By RoA
      • Canada psoriasis drugs market
        • By type
        • By MoA
        • By RoA
  • Europe Psoriasis Drugs Market
    • By type
    • By MoA
    • By RoA
    • By country – Germany, France, U.K., Italy, Spain, and Rest of Europe
      • Germany psoriasis drugs market
        • By type
        • By MoA
        • By RoA
      • France psoriasis drugs market
        • By type
        • By MoA
        • By RoA
      • U.K. psoriasis drugs market
        • By type
        • By MoA
        • By RoA
      • Italy psoriasis drugs market
        • By type
        • By MoA
        • By RoA
      • Spain psoriasis drugs market
        • By type
        • By MoA
        • By RoA
  • Asia-Pacific Psoriasis Drugs Market
    • By type
    • By MoA
    • By RoA
    • By country – China, Japan, India, Australia, South Korea, and Rest of APAC
      • China psoriasis drugs market
        • By type
        • By MoA
        • By RoA
      • Japan psoriasis drugs market
        • By type
        • By MoA
        • By RoA
      • India psoriasis drugs market
        • By type
        • By MoA
        • By RoA
      • Australia psoriasis drugs market
        • By type
        • By MoA
        • By RoA
      • South Korea psoriasis drugs market
        • By type
        • By MoA
        • By RoA
  • Latin America Psoriasis Drugs Market
    • By type
    • By MoA
    • By RoA
    • By country – Brazil, Mexico, and Rest of LATAM
      • Brazil psoriasis drugs market
        • By type
        • By MoA
        • By RoA
      • Mexico psoriasis drugs market
        • By type
        • By MoA
        • By RoA
  • Middle East and Africa Psoriasis Drugs Market
    • By type
    • By MoA
    • By RoA
    • By country – Saudi Arabia, South Africa, and Rest of MEA
      • Saudi Arabia psoriasis drugs market
        • By type
        • By MoA
        • By RoA
      • South Africa psoriasis drugs market
        • By type
        • By MoA
        • By RoA

Browse More Reports

Topical Scar Treatment Market – Geographically, the Chinese topical scar treatment market accounted for the largest share in 2020, and it is also projected to record the highest CAGR during the forecast period. This will be due to the increasing requirement for technologically advanced scar treatment products among the geriatric population, which is rising, in the country. Moreover, the surging disposable income, rising healthcare spending, and increasing prevalence of skin diseases are also driving the market growth in China.

Dermatology Drugs Market – The growing incidence of skin diseases in various countries is the biggest factor propelling the expansion of the dermatology drugs market across the world. Genetic and environmental factors, trauma, and aging are the main factors responsible for skin ailments. As per the World Health Organization (WHO), nearly 900 million people all over the world suffer from skin diseases at any particular time. Furthermore, skin problems are among the most-prevalent human health diseases across the world.

Media Contact
Company Name: P&S Intelligence
Contact Person: Abhishek
Email: Send Email
Phone: +918887787886
Address:Noida Sector 2
City: Noida
State: UP
Country: India
Website: https://www.psmarketresearch.com/market-analysis/psoriasis-drugs-market-outlook

Related Articles